Tag Archives: Johns Hopkins School of Medicine

Scientists Reveal How Induced Pluripotent Stem Cells Differ From Embryonic Stem Cells and Tissue of Derivation

The same genes that are chemically altered during normal cell differentiation, as well as when normal cells become cancer cells, are also changed in stem cells that scientists derive from adult cells, according to new research from Johns Hopkins and Harvard.

Although genetically identical to the mature body cells from which they are derived, induced pluripotent stem cells (iPSCs) are notably special in their ability to self-renew and differentiate into all kinds of cells. And now scientists have detected a remarkable if subtle molecular disparity between the two: They have distinct “epigenetic” signatures; that is, they differ in what gets
Read More…

Stem cells to define the origins of Schizophrenia

Scientific consensus holds that most major mental disorders, such as schizophrenia, are genetically rooted diseases of synapses, the connections between neurons in the brain. Now research has demonstrated how a rare mutation in a suspect gene corrupts the on-off switches of dozens of other genes underlying these connections.

The study appears online in the current issue of the journal Nature. Employing a disease-in-dish technology called induced pluripotent stem cells (iPSCs), the team of investigators, including UC Santa Barbara researchers, studied iPSCs from four members of an American family affected by genetically linked schizophrenia and related mental disorders.

Decades ago, researchers traced
Read More…

Scientists reprogram cancer cells with low doses of epigenetic drugs

Experimenting with cells in culture, researchers at the Johns Hopkins Kimmel Cancer Center have breathed possible new life into two drugs once considered too toxic for human cancer treatment. The drugs, azacitidine (AZA) and decitabine (DAC), are epigenetic-targeted drugs and work to correct cancer-causing alterations that modify DNA.

The researchers said that the drugs also were found to take aim at a small but dangerous subpopulation of self-renewing cells, sometimes referred to as cancer stem cells, which evade most cancer drugs and cause recurrence and spread.

In a report published in the March 20 issue of Cancer Cell, the Johns Hopkins
Read More…

Stem Cells startup to fight ALS

USC Stem Cell researcher Justin Ichida has marshaled the expertise of pharmaceutical company Sanofi and startup DRVision Technologies, along with $1.5 million in federal funding, to find new drugs in the fight against amyotrophic lateral sclerosis, or Lou Gehrig’s disease.

ALS patients suffer from the death of the cells that transmit signals from the brain to the muscles, called motor neurons, leading to progressive paralysis and usually resulting in fatal respiratory failure within three to five years of diagnosis.

The three-year grant comes from the Department of Defense. Each year, the DoD funds two ALS Therapeutic Development Awards because military veterans
Read More…

Young Investigators honored

Johns Hopkins School of Medicine (Photo credit: Wikipedia)

This year marks the 35th annual Young Investigators’ Award program, when School of Medicine trainee researchers are recognized for their stellar accomplishments in the lab. The event will take place from 4 to 6 p.m. on Friday, April 13, in Mountcastle Auditorium in the Preclinical Teaching Building on the East Baltimore campus.

Researchers will celebrate and share their findings, and 13 students and three fellows will receive awards. Each award includes a cash prize and is named for a former member of the Johns Hopkins community.

Each spring students and fellows look forward
Read More…